Drug intelligence / Profile preview

NES100

Development stage
Preclinical
Lead developer
Virpax Pharmaceuticals
Modality
Peptides, Nanoparticles → Drug Delivery Systems
Administration
Intranasal
01

Overview

NES100 is an investigational intranasal drug product containing leucine-enkephalin, a naturally occurring endogenous peptide with analgesic properties. Developed using Molecular Envelope Technology (MET), NES100 is designed to enhance the delivery of enkephalin across the blood-brain barrier via a cartridge-based nasal device that propels the formulation along the olfactory nerve pathway. The MET nanotechnology protects and facilitates transport of this metabolically labile peptide directly to the brain, where it binds to delta opioid receptors to suppress pain. Preclinical studies have demonstrated analgesic potential without typical opioid-related adverse effects such as tolerance, withdrawal, respiratory depression, euphoria, or addiction. NES100 is being developed for acute and chronic non-cancer pain management as a non-addictive alternative to traditional opioids[1][4][5][6][7][8][9].

Brand names
Envelta
Other names
intranasal enkephalin sprayleucine-enkephalin nasal spray
02

Targets

DOR (Opioid Receptor Delta 1)

Beyond the preview

Go deeper on NES100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NES100.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call